CTTACC

The goal of this meeting is to bring together the expertise and input of a multidisciplinary group of blood banks, clinicians, basic scientists, industry, academia, FDA, NIH, AABB, BARDA and DOD representatives to discuss the state of the science and existing barriers in the translation of these novel therapies in trauma and critical care. Regulatory insight will be included from the FDA. ellular therapies, adjuncts to resuscitation and novel blood products represent critical areas in transfusion medicine that have the potential to dramatically improve outcomes in trauma patients and will globally change the face of transfusion medicine in the future. Previous conferences have resulted in multiple cross disciplinary collaborations, grants, pre-clinical studies and clinical trials.